New combo attack on inoperable liver cancer
NCT ID NCT05366829
Summary
This study is testing whether adding an immunotherapy drug called tislelizumab after radiation or other local treatments helps people with liver cancer that cannot be removed by surgery. The goal is to see if this combination can keep the cancer from growing or spreading for a longer time. Researchers will enroll about 35 adults with a specific type of liver cancer to see if the treatment is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10451, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.